Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Kasey Lyn Couts

TitleAsst Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Biography 
    Collapse education and training
    Valparaiso University, Valparaiso, INB.S.05/2004Biochemistry
    University of Colorado- Boulder, Boulder, COPh.D.12/2010Biochemistry

    Collapse Overview 
    Collapse overview
    My research interests are primarily focused on understanding the development and pathobiology underlying rare melanomas (such as mucosal, acral, and ocular melanomas) in order to 1) identify risk factors to improve prevention and early detection, 2) develop novel tumor/blood diagnostics for rare melanoma subtypes, 3) establish methods for halting progression and eliminating micro-metastatic disease, and 4) improve efficacy of current therapies (targeted and immunotherapies) and develop new treatment modalities which are effective for rare melanoma patients.

    Collapse Research 
    Collapse research activities and funding
         (Kasey Couts)Jan 1, 2016 - Jun 1, 2017
    Paul R. Ohara II Seed Grant Award
    Gene fusions as actionable therapeutic targets in acral lentiginous melanomas
    Role Description: Characterize and test efficacy of targeted inhibitors for gene fusions in acral melanomas.
    Role: Principle Investigator

         (Kasey Couts)Apr 1, 2016 - Mar 31, 2017
    Activating gene fusions as targets in malignant melanoma
    Role Description: Characterize gene fusions in pan-negative melanomas using melanoma PDX models.
    Role: Principle Investigator

         (Kasey Couts)Jul 1, 2017 - Dec 31, 2018
    Cancer League of Colorado
    Improving targeted therapy in melanomas with BRAF fusions
    Role Description: Test novel combinatorial treatment strategies for BRAF fusions.
    Role: Principle Investigator

         (Kasey Couts)Jan 1, 2018 - Dec 31, 2018
    American Cancer Society Institutional Seed Grant
    Targeting cell cycle structural variants in acral and mucosal melanomas
    Role Description: Investigate cell cycle structural variants and cell cycle based therapies in acral and mucosal melanomas.
    Role: Principle Investigator

         (Kasey Couts)Mar 1, 2019 - Feb 28, 2020
    The role of BRAF fusions in melanoma anti-tumor immune responses
    Role Description: Determine how BRAF fusions promote anti-tumor immunotherapy responses in melanoma patients.
    Role: Principle Investigator

         (Kasey Couts)Jul 1, 2019 - Jun 30, 2022
    Patten-Davis Foundation
    CU Center for Rare Melanomas
    Role Description: Establish a first-of-its-kind joint research and clinical center for improving care of patients with rare, non-UV associated melanomas.
    Role: Co-Director

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, Aisner DL, Robinson WA, Couts KL. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020 12; 30(6):562-573. PMID: 33156595.
      View in: PubMed
    2. Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443. PMID: 32513939.
      View in: PubMed
    3. Borgers JSW, Tobin RP, Vorwald VM, Smith JM, Davis DM, Kimball AK, Clambey ET, Couts KL, McWilliams JA, Jordan KR, Torphy RJ, Schulick R, McCarter MD. High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell Changes. Immunohorizons. 2020 02 18; 4(2):82-92. PMID: 32071067.
      View in: PubMed
    4. Tobin RP, Jordan KR, Kapoor P, Spongberg E, Davis D, Vorwald VM, Couts KL, Gao D, Smith DE, Borgers JSW, Robinson S, Amato C, Gonzalez R, Lewis KD, Robinson WA, Borges VF, McCarter MD. IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Front Oncol. 2019; 9:1223. PMID: 31781510.
      View in: PubMed
    5. Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL. BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 2019 02; 38(8):1296-1308. PMID: 30254212.
      View in: PubMed
    6. Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018 09 05; 9(9):907. PMID: 30185782.
      View in: PubMed
    7. Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231. PMID: 29054983.
      View in: PubMed
    8. Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 06; 27(3):189-199. PMID: 28296713.
      View in: PubMed
    9. Turner J, Couts K, Sheren J, Saichaemchan S, Ariyawutyakorn W, Avolio I, Cabral E, Glogowska M, Amato C, Robinson S, Hintzsche J, Applegate A, Seelenfreund E, Gonzalez R, Wells K, Bagby S, Tentler J, Tan AC, Wisell J, Varella-Garcia M, Robinson W. Kinase gene fusions in defined subsets of melanoma. Pigment Cell Melanoma Res. 2017 01; 30(1):53-62. PMID: 27864876.
      View in: PubMed
    10. Nguyen N, Couts KL, Luo Y, Fujita M. Understanding melanoma stem cells. Melanoma Manag. 2015; 2(2):179-188. PMID: 26594315.
      View in: PubMed
    11. Lee T, Wang N, Houel S, Couts K, Old W, Ahn N. Dosage and temporal thresholds in microRNA proteomics. Mol Cell Proteomics. 2015 Feb; 14(2):289-302. PMID: 25467838.
      View in: PubMed
    12. Couts KL, Anderson EM, Gross MM, Sullivan K, Ahn NG. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene. 2013 Apr 11; 32(15):1959-70. PMID: 22751131.
      View in: PubMed
    13. Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC, Ahn NG. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene. 2009 Jul 30; 28(30):2697-709. PMID: 19483722.
      View in: PubMed
    14. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell. 2009 Apr 10; 34(1):115-31. PMID: 19362540.
      View in: PubMed
    15. Roberts EC, Hammond K, Traish AM, Resing KA, Ahn NG. Identification of G2/M targets for the MAP kinase pathway by functional proteomics. Proteomics. 2006 Aug; 6(16):4541-53. PMID: 16858730.
      View in: PubMed
    Couts's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)